“In effect, the era of high list prices and high rebates for insulin is over” In case you missed it, Alex Brill, founder and CEO of Matrix Global Advisors (MGA) and former policy director and chief economist for the House
JC Scott speaks with Doug Long, Vice President of Industry Relations at IQVIA, about the impact of COVID-19 on the pharmaceutical market. IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare
Unlocking an Affordable Future: Key #1 Ensure System Sustainability ENSURE SYSTEM SUSTAINABILITY BY PROMOTING COMPETITION A competitive private market is the best way to manage drug costs. Interventions should be focused on fixing specific market failures or gaps rather than
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively leverage competition to reduce drug costs for health plan sponsors and patients. As biosimilar competition
(Washington, D.C.) – As independent drugstore lobbyists descend on Albany for their special interest lobby day, the Pharmaceutical Care Management Association (PCMA) released the following statement: “Pharmacy benefit managers (PBMs) advocate on behalf of New York’s consumers and health plan sponsors by negotiating
Mark Merritt, chief executive of PCMA, dislikes the proposal and believes the Medicare coverage is a “sound program”
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
(Washington, D.C.) — As drugstore lobbyists descend on Albany today, it is important to highlight how pharmacy benefit managers (PBMs) advocate for consumers and health plan sponsors in the fight to keep prescription drugs accessible and affordable. It is equally
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the eve of Governor Andrew Cuomo’s 2020 State of the State Address and the start of the state legislative session in Albany:
Study Finds Yearly Cost of Patent Thickets on Five Top-Selling Brand Name Drugs Ranges from $1.8 to $7.6 Billion.
©2024 PCMA. All Rights Reserved.
